ShiraTronics raises $66M in Series B funding for FDA-approved migraine therapy device trial.

ShiraTronics has raised $66 million in Series B funding to support its FDA-approved RELIEV-CM2 trial for the Migraine Therapy System, targeting treatment-resistant chronic migraine patients. This minimally invasive device, which delivers electrical pulses to nerve areas associated with migraines, aims to improve patient outcomes. The funding will also help secure FDA premarket approval and launch the therapy commercially, enhancing options for patients dissatisfied with current treatments.

October 09, 2024
6 Articles

Further Reading